In other type of cancers, EZH2 has been shown to suppress several metabolic activities, including branched amino acid (BCAA) metabolism, TCA cycle (IDH1), mTOR (mammalian target of rapamycin) signaling, and glutamine metabolism (Dann et al., 2015; Gu et al., 2019). Here, MTOR is linked to cancer.